I’m not sure if this has been posted but Melcangi’s study’s transcript has been released (the one we helped fund). It can be found here:
I don’t think there’s anything groundbreaking here but perhaps someone who’s more into the science can highlight anything meaningful.
On an unrelated note, sage-217 is up on clinicaltrials.gov! They’re aiming to complete Phase 3 by November 2019. Coupled with their priority review status, a PDUFA date end of 2020 seems likely. Study can be found here: https://www.clinicaltrials.gov/ct2/show/NCT03672175?term=sage-217&rank=4
Thanks guys, be well.